Journal article
Iodine-125 labeled Australian frog tree host-defense peptides caerin 1.1 and 1.9 better inhibit human breast cancer cells growth than the unlabeled peptides.I25I-caerin 1.9 may better be used for the treatment of breast cancer
Hellenic Journal of Nuclear Medicine, Vol.21(2), pp.115-120
2018
PMID: 30006645
Abstract
Objective: We recently showed that host defense caerin peptides isolated from Australian frog tree were able to inhibit cervical cancer tumour cell growth in vitro. We wished to determine if radioactive isotope iodine-125 (125I) can be labeled to caerin 1.9 peptide and if this peptide is bioactive for breast cancer cells treatment. Subjects and methods: The biological function of caerin (1.1 and 1.9) peptides were investigated by in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay. The anti-cancer effect of 125I labeled caerin 1.9 was compared with unlabeled caerin 1.9 peptide. The tissue distribution of 125I labeled caerin 1.9 peptide was further studied in mice. Results: In the current paper, we demonstrated that caerin peptides (1.1 and 1.9) were separately able to inhibit the viability of two breast cancer cell lines in vitro and this inhibition was more profound when these peptides were simultaneously applied. Moreover, 125I can be stably attached to caerin 1.9 peptide with high efficiency. Iodine-125 labeled caerin 1.9 inhibited breast cancer cells line MCF-7 viability more efficiently than free 125I and also than unlabeled caerin 1.9. Additionally, iodine-125 labeled caerin 1.9 in vivo imaging demonstrated that although slightly, it could be accumulated in tumor tissue. Conclusion: Our results from this totally original study indicated that radioactive isotope 125I labeled to caerin peptide 1.9 may be used to treat breast cancer while at the same time the response to treatment may be monitored by simultaneous imaging.
Details
- Title
- Iodine-125 labeled Australian frog tree host-defense peptides caerin 1.1 and 1.9 better inhibit human breast cancer cells growth than the unlabeled peptides.I25I-caerin 1.9 may better be used for the treatment of breast cancer
- Authors
- Jianwei Yuan (Author) - Guangdong Pharmaceutical UniversityXinchao You (Author) - Guangdong Pharmaceutical UniversityGuoying Ni (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and EngineeringTianfang Wang (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and EngineeringShelley F Walton (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and EngineeringXuan Pan (Author) - Guangdong Pharmaceutical UniversityXiao Song Liu (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and Engineering
- Publication details
- Hellenic Journal of Nuclear Medicine, Vol.21(2), pp.115-120
- Publisher
- Hellenic Society of Nuclear Medicine
- Date published
- 2018
- ISSN
- 1108-1430; 1790-5427
- PMID
- 30006645
- Organisation Unit
- School of Science and Engineering - Legacy; University of the Sunshine Coast, Queensland; GeneCology Research Centre - Legacy; School of Health and Sport Sciences - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99451369702621
- Output Type
- Journal article
Metrics
5 File views/ downloads
499 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Radiology, Nuclear Medicine & Medical Imaging
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites